Personalized medicinePub Date : 2023-07-01Epub Date: 2023-09-25DOI: 10.2217/pme-2022-0070
Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken
{"title":"Cost-effectiveness of alternative <i>NTRK</i> testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.","authors":"Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken","doi":"10.2217/pme-2022-0070","DOIUrl":"10.2217/pme-2022-0070","url":null,"abstract":"<p><p><b>Aim:</b> To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. <b>Methods:</b> Four testing strategies where adult cancer patients received entrectinib if they tested positive for <i>NTRK</i> gene fusions compared with 'no testing' and standard of care (SoC) for all patients were evaluated. <b>Results:</b> Immunohistochemistry for all patients followed by RNA-based next-generation sequencing after a positive result was the optimal strategy in all included countries. However, the incremental net monetary benefit compared with SoC was negative in all countries, ranging between international euros (int€) -206 and -404. In a subgroup analysis with only <i>NTRK</i>-positive patients, the incremental net monetary benefit was int€ 8405 in England, int€ -53,088 in Hungary and int€ 54,372 in The Netherlands. <b>Conclusion:</b> Using the cost-effectiveness thresholds recommended by national guidelines, none of the testing strategies were cost-effective compared with no testing. The implementation of entrectinib is unlikely to become cost-effective in Hungary, due to the large cost difference between the entrectinib and SoC arms, while there might be more potential in England and The Netherlands.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":"20 4","pages":"321-338"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2023-07-01Epub Date: 2023-09-22DOI: 10.2217/pme-2022-0074
Maureen Rutten-van Mölken, Matthijs Versteegh, Balázs Nagy, Sarah Wordsworth
{"title":"HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead.","authors":"Maureen Rutten-van Mölken, Matthijs Versteegh, Balázs Nagy, Sarah Wordsworth","doi":"10.2217/pme-2022-0074","DOIUrl":"https://doi.org/10.2217/pme-2022-0074","url":null,"abstract":"","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":"20 4","pages":"299-303"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
